Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

This editorial refers to ‘Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the...

Anthony A. Bavry, M.D., M.P.H.,...

Debabrata Mukherjee, MD,...

Investigators sought to examine the effect of vericiguat on cardiovascular outcomes and changes in NT-proBNP levels in patients with heart...

Even after accounting for “real world” rates of drug discontinuation, discharge on sacubitril/valsartan after conferred a small, but significant, survival advantage which does not...

Empagliflozin for 12 weeks added to guideline-directed HF therapy did not improve LV contractile reserve in patients with HF and reduced ejection...